Pliant Therapeutics (PLRX) Profit After Tax (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Profit After Tax of -$20.4 million for Q1 2026, down 12471.6% year-over-year from N/an in Q1 2025, and up 86.37% quarter-over-quarter from -$149.4 million in Q4 2025.
Pliant Therapeutics (PLRX) Profit After Tax (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Profit After Tax for 8 consecutive years, with -$20.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 12471.6% year-over-year to -$20.4 million; the TTM figure through Mar 2026 stood at -$213.0 million (down 103.25% YoY), while the FY2025 annual figure was -$149.7 million, up 28.83% from the prior year.
- Profit After Tax improved to -$20.4 million in Q1 2026 per PLRX's latest filing, from -$149.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at $1.5 million in Q3 2024 and bottomed at -$149.4 million in Q4 2025.
- Historically, Profit After Tax has averaged -$33.6 million across 5 years, with a median of -$31.8 million in 2022.
- Annual changes were most pronounced in 2022 — Profit After Tax sank 318000.0% — and 2024, when it soared 338.62%.
- Pliant Therapeutics' Profit After Tax stood at $496000.0 in 2022, then plunged by 7923.79% to -$38.8 million in 2023, then declined by 29.51% to -$50.3 million in 2024, then sank by 197.25% to -$149.4 million in 2025, then soared by 86.37% to -$20.4 million in 2026.
- Business Quant data shows PLRX's Profit After Tax at -$20.4 million in Q1 2026, -$149.4 million in Q4 2025, and $35000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | -22.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.43 Mn |
| Mar 31, 2026 | -20.37 Mn |
| Dec 31, 2025 | -149.39 Mn |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | -43.30 Mn |
| Mar 31, 2025 | -162,000.00 |
| Dec 31, 2024 | -50.26 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | -55.85 Mn |
| Mar 31, 2024 | -46.96 Mn |
| Dec 31, 2023 | -38.81 Mn |
| Sep 30, 2023 | 334,000.00 |
| Jun 30, 2023 | -41.19 Mn |
| Mar 31, 2023 | -37.55 Mn |
| Dec 31, 2022 | 496,000.00 |
| Sep 30, 2022 | -31.81 Mn |
| Jun 30, 2022 | -29.55 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | -24.70 Mn |
| Sep 30, 2021 | -10,000.00 |